TY  - JOUR
AU  - Jung, Seungyoun
AU  - Allen, Naomi
AU  - Arslan, Alan A
AU  - Baglietto, Laura
AU  - Barricarte, Aurelio
AU  - Brinton, Louise A
AU  - Egleston, Brian L
AU  - Falk, Roni T
AU  - Fortner, Renée T
AU  - Helzlsouer, Kathy J
AU  - Gao, Yutang
AU  - Idahl, Annika
AU  - Kaaks, Rudolph
AU  - Krogh, Vittorio
AU  - Merritt, Melissa A
AU  - Lundin, Eva
AU  - Onland-Moret, N Charlotte
AU  - Rinaldi, Sabina
AU  - Schock, Helena
AU  - Shu, Xiao-Ou
AU  - Sluss, Patrick M
AU  - Staats, Paul N
AU  - Sacerdote, Carlotta
AU  - Travis, Ruth C
AU  - Tjønneland, Anne
AU  - Trichopoulou, Antonia
AU  - Tworoger, Shelley S
AU  - Visvanathan, Kala
AU  - Weiderpass, Elisabete
AU  - Zeleniuch-Jacquotte, Anne
AU  - Dorgan, Joanne F
TI  - Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
JO  - International journal of cancer
VL  - 142
IS  - 2
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2018-00057
SP  - 262 - 270
PY  - 2018
AB  - Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95
KW  - Biomarkers (NLM Chemicals)
KW  - Anti-Mullerian Hormone (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:28921520
C2  - pmc:PMC5749630
DO  - DOI:10.1002/ijc.31058
UR  - https://inrepo02.dkfz.de/record/131758
ER  -